Vest Financial LLC Sells 224,532 Shares of Kenvue Inc. (NYSE:KVUE)

Vest Financial LLC trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,471,014 shares of the company's stock after selling 224,532 shares during the period. Vest Financial LLC owned approximately 0.13% of Kenvue worth $52,756,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. AMF Tjanstepension AB raised its stake in Kenvue by 187.3% in the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company's stock worth $2,787,000 after buying an additional 78,540 shares in the last quarter. Mather Group LLC. grew its stake in Kenvue by 62.0% during the 3rd quarter. Mather Group LLC. now owns 6,857 shares of the company's stock valued at $159,000 after purchasing an additional 2,625 shares during the last quarter. Atomi Financial Group Inc. acquired a new position in Kenvue in the 3rd quarter worth approximately $212,000. Perpetual Ltd raised its stake in shares of Kenvue by 2.6% during the 3rd quarter. Perpetual Ltd now owns 25,380 shares of the company's stock valued at $587,000 after buying an additional 652 shares during the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in Kenvue in the 3rd quarter worth approximately $241,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.05 on Wednesday, hitting $20.96. The company's stock had a trading volume of 10,316,961 shares, compared to its average volume of 12,673,827. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $40.19 billion, a price-to-earnings ratio of 39.55, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The stock's 50-day moving average is $21.41 and its two-hundred day moving average is $22.03.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. Kenvue's payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KVUE. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Bank of America increased their target price on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Finally, Canaccord Genuity Group lowered their price target on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.